Abstracts tagged "Biologics"

Abstract Number: 609 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)
Yoshiya Tanaka¹, Kiyotaka Yamazaki², Ryo Nakajima², Shuichi Komatsu³, Naoki Agata⁴, Ataru Igarashi⁵, Toshiro Tango⁶ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, ³Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, ⁴Medical Communication, Medical, AbbVie GK, Tokyo, Japan, ⁵Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, ⁶Center for Medical Statistics, Tokyo, Japan, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Patients with Rheumatoid Arthritis (RA) experience loss of productivity such as missing their work and lowering their performance incurred by impaired physical functioning. Treatment…
Abstract Number: 1635 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Dae-Hyun Yoo¹, Ljubinka Bozic Majstorovic², Alfredo Berrocal Kasay³, Elias Chalouhi El-Khouri⁴, Fedra Irazoque-Palazuelos⁵, Francisco Cons Molina⁶, Pedro Miranda⁷, Pavel Shesternya⁸, Francisco G. Medina-Rodriguez⁹, Piotr Wiland¹⁰, Slawomir Jeka¹¹, Olena Garmish¹², Pawel Hrycaj¹³, Dmytro Rekalov¹⁴, Natalia Fomina¹⁵, Devy Zisman¹⁶, Yong-Beom Park¹⁷, Young Mo Kang¹⁸, Chang-Hee Suh¹⁹, Seung Cheol Shim²⁰, Sang Joon Lee²¹, Sung Young Lee²² and Won Park²³, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Clinical Centre Banja Luka, Bonja Luka, Bosnia and Herzegovina, ³ABK Reuma SRL – Medicentro Biociencias, Lima, Peru, ⁴Clinica Internacional, Lima, Peru, ⁵Centro de Invstigacion y Tratamiento Reumatologico S.C, Mexico City, Mexico, ⁶Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁷Centro De Estudios Reumatológicos, Santiago, Chile, ⁸State Budgetary Educational Institution of High Professional Education "Krasnoyarsk state medical university n.a. professor V.F.Voino-Yasenetsky" Ministry of Health of Russian Federation, Krasnoyarsk, Russian Federation, ⁹Biologics Especializados SA, Mexico City, Mexico, ¹⁰Uniwersytecki Szpital Kliniczny im. Jana Mikulicza- Radeckigo, Wroclaw, Poland, ¹¹Department of Rheumatology and Connective Tissue Diseases, 2nd University Hospital, CM UMK, Bydgoszcz, Poland, ¹²Institute of Cardiology named by M.D. Strazhesko NAMS of Ukraine, Kyiv, Ukraine, ¹³Rheumatology and Clinical Immunology, Poznañ University of Medical Sciences, Poznan, Poland, ¹⁴Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, ¹⁵Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation, ¹⁶The Lady Davis, Haifa, Israel, ¹⁷Dept of Internal Medicine, Severance Hospital, Seoul, Korea, The Republic of, ¹⁸Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of, ¹⁹Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, The Republic of, ²⁰Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ²¹CELLTRION, Inc., Incheon, South Korea, ²²Clinical Planning Department, CELLTRION, Inc., Incheon, South Korea, ²³Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea
Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Result from Phase 3 Randomized Controlled Trial over 24…
Abstract Number: 2610 • 2016 ACR/ARHP Annual Meeting
Immunogenicity Assessment of Biologics in Clinical Studies in Chronic Inflammatory Disease: A Systematic Review
Boris Gorovits¹, Daniel Baltrukonis², Indranil Bhattacharya³, Mary A Birchler⁴, Deborah Finco², Daniel Sikema⁴, Michael S Vincent⁵, Sadiq Lula⁶, Lisa Marshall⁷ and Timothy Hickling¹, ¹Pfizer, Andover, MA, ²Pfizer, Groton, CT, ³Clinical Pharmacology, Pfizer, Cambridge, MA, ⁴Clinical Immunology, Glaxo Smith Kline BioPharmaceuticals, Upper Merion, PA, ⁵Inflammation and Immunology Research Unit, Pfizer, Cambridge, MA, ⁶Envision Pharma Group, London, United Kingdom, ⁷Inflammation Global Medical Affairs, Pfizer, Collegeville, PA
Background/Purpose: A portion of patients without clinical response to anti-inflammatory biologics have been shown to develop anti-drug antibodies (ADA).1 ADA prevalence varies widely among biologics,…
Abstract Number: 610 • 2016 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials
Erin Murray¹, Yekaterina Butylkova¹, Alexandra Ellis¹, Martha Skup², Jasmina Kalabic³ and Vishvas Garg⁴, ¹Doctor Evidence, Santa Monica, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc, North Chicago, IL
Background/Purpose: Previously, several studies have meta-analyzed clinical, functional or structural efficacy of biologics in treating rheumatoid arthritis (RA) patients. However, the comparative efficacy of biologics…
Abstract Number: 1651 • 2016 ACR/ARHP Annual Meeting
A Case Series on Patients on Tofacitinib in Combination with a Biologic
Nashla Barroso¹ and Daniel E. Furst², ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although there have been significant advances in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). patients can experience a lack of or…
Abstract Number: 2631 • 2016 ACR/ARHP Annual Meeting
Trends and Factors Associated with Use of Biologic Agents As Monotherapy Among US Patients with Rheumatoid Arthritis
Chieh-I Chen¹, Wenhui Wei², Stuart Blackburn³, Emma Sullivan³ and James Piercy³, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi US, Inc., Bridgewater, NJ, ³Adelphi Real World, Manchester, United Kingdom
Background/Purpose: For patients with rheumatoid arthritis (RA) receiving a biologic disease-modifying antirheumatic drug (bDMARD), the current standard of care is to use the bDMARD concurrently…
Abstract Number: 624 • 2016 ACR/ARHP Annual Meeting
Association Between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis
Yoshikazu Ogawa¹, Nobunori Takahashi², Toshihisa Kojima³ and Naoki Ishiguro⁴, ¹orthopedic surgery, Sakashita Hospital, Nakatsugawa, Japan, ²Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Nagoya University, Nagoya, Japan
Background/Purpose: In general, the concomitant use of methotrexate (MTX) and biologic disease-modifying antirheumatic drugs (bDMARDS) plays an important role in treating bio-naïve patients with rheumatoid…
Abstract Number: 1686 • 2016 ACR/ARHP Annual Meeting
Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab
Diamant Thaci¹, Akimichi Morita², Julie Birt³, Chen-Yen Lin³, Catherine L. Shuler³ and Alice B. Gottlieb⁴, ¹Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ²Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴Tufts University School of Medicine, Boston, MA
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. In a phase 3 study, IXE was superior to placebo (PBO) in achieving…
Abstract Number: 2636 • 2016 ACR/ARHP Annual Meeting
No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review
L. Tweehuysen¹, C.H. van den Ende², F.M.M. Beeren², E.M.J. Been², F.H.J. van den Hoogen^3,4 and A.A. den Broeder³, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Tapering of biologics in rheumatoid arthritis (RA) is based on a trial-and-error disease activity guided strategy, because it is not known in advance which…
Abstract Number: 13L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Hideto Akama⁵, Nobuyuki Yasuda⁵, Fumitoshi Tago⁵, Makoto Kawakubo⁵, Seiichiro Hojo⁵, Tetsu Kawano⁶ and Toshio Imai⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan, ³Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵EISAI Co. Ltd., Tokyo, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 603 • 2015 ACR/ARHP Annual Meeting
Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset
Elizabeth M.A. Hensor^1,2, Edward M. Vital^1,2 and Paul Emery^1,2, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Seronegative RA patients have inferior clinical response to rituximab [1]. However, there is significant heterogeneity in this group of patients for baseline clinical features…
Abstract Number: 1997 • 2015 ACR/ARHP Annual Meeting
Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis
James R. O'Dell¹, Melanie Rohr¹, Stanley B. Cohen², J Carter Thorne³ and Ted R. Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: MTX is the anchor DMARD for RA treatment, but there is limited information about its appropriate use in clinical practice. This claims analysis was…
Abstract Number: 2841 • 2015 ACR/ARHP Annual Meeting
Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Philip J. Mease¹, Tamara Lesperance², Neil Accortt², David Collier², Mei Liu³, Marc Mason⁴ and Sabrina Deveikis⁴, ¹Clinical Professor, University of Washington School of Medicine, Seattle, WA, ²Amgen, Inc., Thousand Oaks, CA, ³352 Turnpike Rd, Corrona, LLC, Southborough, MA, ⁴Corrona, LLC., Southborough, MA
Background/Purpose: Over the past decade, the treatment of PsA has improved significantly. The purpose of this study was to describe real-world treatment patterns among PsA…
Abstract Number: 610 • 2015 ACR/ARHP Annual Meeting
Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Biologic Disease-Modifying Therapy Compared with Conventional Therapy
Hyun Mi Kwon, Sang Jin Lee, Ji Ae Yang, Jin Young Moon, Eun Young Ahn, Jin Kyun Park, Eun Young Lee, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) infection. RA treatment including immunosuppressant medications could further exacerbate the risk.…
Abstract Number: 2038 • 2015 ACR/ARHP Annual Meeting
Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids
Antoine P. Brezin¹, Phillippe Kestelyn², Joachim Van Calster³, Glenn J. Jaffe⁴, Jennifer E. Thorne⁵, David Scales⁶, Pablo Franco⁷, Andrew D. Dick^8,9,10, Quan Dong Nguyen¹¹, Eric B. Suhler^12,13, Anne Camez¹⁴, Alexandra P. Song¹⁵, Martina Kron¹⁴, Samir Tari¹⁵, James T. Rosenbaum^16,17 and Arnd Heiligenhaus¹⁸, ¹Université Paris Descartes, Hôpital Cochin, Paris, France, ²Ghent University Hospital, Ghent, Belgium, ³University Hospitals Leuven, Leuven, Belgium, ⁴Duke University, Durham, NC, ⁵Johns Hopkins Medical Institute, Baltimore, MD, ⁶University of Texas Health Science Center, San Antonio, TX, ⁷Organización Médica de Investigación (OMI), Buenos Aires, Argentina, ⁸National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital, London, United Kingdom, ⁹University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ¹⁰University College London, Institute of Ophthalmology, London, United Kingdom, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, ¹²VA Portland Health Care System, Portland, OR, ¹³Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, ¹⁴Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ¹⁵AbbVie Inc., North Chicago, IL, ¹⁶Devers Eye Institute, Legacy Hospital system, Portland, OR, ¹⁷Casey Eye Institute, Oregon Health & Science University, Portland, OR, ¹⁸Department of Ophthalmology at St. Franziskus Hospital Muenster, University of Duisberg-Essen, Muenster, Germany
Background/Purpose: Corticosteroids, currently the mainstay of uveitis treatment, are associated with adverse events and are not always fully effective. Multiple reports describe the use of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].